GMRI Contributes to Prestigious Book on ACE Inhibitors

ACE Inhibitors book cover copyThe Gillies McIndoe Research Institute (GMRI) has contributed a chapter to the most authoritative reference collection of expert articles ever put together on ACE inhibitors.

“The GMRI was invited last year to contribute a chapter to the two-volume book on the state-of-the-art of ACE inhibitors,” says Dr Swee Tan.

Top experts in the various fields of nephrology, hypertension, cardiovascular medicine, pharmacotherapeutics and related fields from around the world, drawn from all five continents, have contributed essays, original papers, reviews and editorial opinions in the book.

The book, entitled ACE Inhibitors, Medical Use, Mechanisms of Action, Potential Adverse Effects and Related Topics, has recently been published. It is edited by Professor Macaulay AC Onuigbo of the Mayo Clinic in Rochester, USA.

The chapter the GMRI contributed to the book was titled Treatment of Infantile Haemangioma with an ACE Inhibitor: A Paradigm Shift.

The authors are Drs Tinte Itinteang, Paul Davis and Swee Tan. The institutions involved are the GMRI and the Centre for the Study and Treatment of Vascular Birthmarks, Wellington Regional Plastic, Maxillofacial & Burns Unit, Hutt Hospital.

The chapter includes findings of the world’s first ever clinical trial using captopril, an ACE inhibitor for treating strawberry birthmarks, conducted by the GMRI team together with colleagues at Hutt Hospital and Starship Hospital in Auckland. The before and after treatment photos of Zoe were included in the chapter.

We are also heartened that our work has been endorsed with commentary by some highly-regarded members of the international medical community. A special preview in the book was provided by Professor Zbylut J Twarddowski of the University of Missouri in the USA, an excerpt of which states:

“Tan et al, from….Wellington, New Zealand, report a novel and fascinating paradigm shift in the utilisation of ACE to treat infantile haemangiomas….the authors conclude that this concept underscores novel understanding and implications of ACE inhibition in human development, infantile haemangioma and other tumours in general. Drug manufacturers and cancer research must take note of this new major paradigm shift.”

Zoe aged five months before and six months after captopril treatment

Zoe aged five months before and six months after captopril treatment